Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia Trial of GST-HG171 in Healthy Subjects
NCT05668897Phase 1Completed
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atilotrelvir in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Fujian Akeylink Biotechnology Co., Ltd. Primary endpoint: Safety and Tolerability at Day 9. Started Oct 2022; status: completed.
02
Drugs
atilotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05668897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668897.